These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

808 related articles for article (PubMed ID: 23225012)

  • 1. Parkinson's disease.
    Mhyre TR; Boyd JT; Hamill RW; Maguire-Zeiss KA
    Subcell Biochem; 2012; 65():389-455. PubMed ID: 23225012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
    Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial Dysfunction, Protein Misfolding and Neuroinflammation in Parkinson's Disease: Roads to Biomarker Discovery.
    Picca A; Guerra F; Calvani R; Romano R; Coelho-Júnior HJ; Bucci C; Marzetti E
    Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling Lewy pathology propagation in Parkinson's disease.
    Luk KC; Lee VM
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1(0 1):S85-7. PubMed ID: 24262196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors.
    Pajarillo E; Rizor A; Lee J; Aschner M; Lee E
    Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):1992-2000. PubMed ID: 30481588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.
    Henderson MX; Trojanowski JQ; Lee VM
    Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. α-Synuclein and dopamine at the crossroads of Parkinson's disease.
    Venda LL; Cragg SJ; Buchman VL; Wade-Martins R
    Trends Neurosci; 2010 Dec; 33(12):559-68. PubMed ID: 20961626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of microRNA deregulation on chaperone-mediated autophagy and α-synuclein pathology in Parkinson's disease.
    Alvarez-Erviti L; Seow Y; Schapira AH; Rodriguez-Oroz MC; Obeso JA; Cooper JM
    Cell Death Dis; 2013 Mar; 4(3):e545. PubMed ID: 23492776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson's disease and α-synuclein expression.
    Devine MJ; Gwinn K; Singleton A; Hardy J
    Mov Disord; 2011 Oct; 26(12):2160-8. PubMed ID: 21887711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synphilin isoforms and the search for a cellular model of lewy body formation in Parkinson's disease.
    Eyal A; Engelender S
    Cell Cycle; 2006 Sep; 5(18):2082-6. PubMed ID: 16969096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological roles of α-synuclein in neurological disorders.
    Vekrellis K; Xilouri M; Emmanouilidou E; Rideout HJ; Stefanis L
    Lancet Neurol; 2011 Nov; 10(11):1015-25. PubMed ID: 22014436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
    Conway KA; Harper JD; Lansbury PT
    Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients.
    Ho CY; Troncoso JC; Knox D; Stark W; Eberhart CG
    Brain Pathol; 2014 Jan; 24(1):25-32. PubMed ID: 23714377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice.
    Froula JM; Castellana-Cruz M; Anabtawi NM; Camino JD; Chen SW; Thrasher DR; Freire J; Yazdi AA; Fleming S; Dobson CM; Kumita JR; Cremades N; Volpicelli-Daley LA
    J Biol Chem; 2019 Jul; 294(27):10392-10406. PubMed ID: 31142553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cellular pathology of Parkinson's disease.
    Takahashi H; Wakabayashi K
    Neuropathology; 2001 Dec; 21(4):315-22. PubMed ID: 11837539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of sheep α-synuclein provides a molecular strategy for the reduction of fibrillation.
    Bickle L; Hopwood JJ; Karageorgos L
    Biochim Biophys Acta Proteins Proteom; 2017 Mar; 1865(3):261-273. PubMed ID: 28007442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.